SEOUL, Jan. 23 (Korea Bizwire) — Celltrion Inc.’s autoimmune disease treatment, SteQeyma, has been launched in five major European nations, the Korean company said Thursday. SteQeyma, an ustekinumab biosimilar treatment for multiple chronic inflammatory diseases, was released in France on Monday (local time), following its launch in Italy and Spain earlier this month, according to [...]
SEOUL, Dec. 9 (Korea Bizwire) — South Korea’s pharmaceutical giant Celltrion Inc. said Monday that it has received approval from Canadian health authorities for a biosimilar treatment for allergic asthma. The company said that its biosimilar, Omlyclo, a version of Xolair, has been approved by Health Canada, adding that studies have demonstrated its equivalent performance [...]
SEOUL, Aug. 16 (Korea Bizwire) — Celltrion Inc., a South Korean biopharmaceutical firm, said Friday it has decided not to merge with its chemical drug-producing affiliate, Celltrion Pharm Inc., as shareholders disagreed on the planned merger. The decision was made in board meetings of the two companies held earlier in the day, Celltrion said. In [...]
SEOUL, Apr. 23 (Korea Bizwire) — Celltrion Inc. saw the combined market share of its autoimmune biosimilar infliximab products, Remsima and Remsima SC, rising in five European nations, company officials said Tuesday. The combined market share of Remsima and the subcutaneous version of the drug hit 74 percent in Britain, Germany, France, Spain and Italy [...]
SEOUL, Mar. 18 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. said Monday its new autoimmune disease treatment, Zymfentra, has made a debut in the U.S. market. Zymfentra, a subcutaneous injection formulation of Celltrion’s infliximab Remsima, won approval from the U.S. Food and Drug Administration last year for use on patients who suffer ulcerative [...]
SEOUL, Nov. 30 (Korea Bizwire) — Celltrion Healthcare Co. said Thursday its new autoimmune disease treatment, Zymfentra, will make its U.S. market debut on Feb. 29 next year. Zymfentra, a subcutaneous injection formulation of Celltrion’s infliximab Remsima, won approval from the U.S. Food and Drug Administration last month. The sales affiliate of South Korean pharmaceutical [...]
SEOUL, Nov. 30 (Korea Bizwire) – This year, the aggregate value of stock options granted by publicly listed companies in South Korea has dipped to 950 billion won, marking the first time in five years that it has fallen below the 1 trillion won threshold. The decline in the stock market has been a contributing factor, [...]
SEOUL, Oct. 23 (Korea Bizwire) — South Korea’s major pharmaceutical firm Celltrion Inc. said Monday its new autoimmune disease treatment has won approval from the U.S. Food and Drug Administration (FDA). The FDA approved Celltrion’s Zymfentra, a subcutaneous injection formulation of its infliximab Remsima, for maintenance therapy in adults with moderately to severely active ulcerative [...]
SEOUL, Oct. 23 (Korea Bizwire) — Shareholders of pharmaceutical firm Celltrion Inc. on Monday approved a plan to merge with its sales and marketing affiliate Celltrion Healthcare Co., company officials said. Celltrion Healthcare’s merger with Celltrion was also approved by the affiliate’s shareholders earlier in the day. The approval came about three months after Celltrion [...]
SEOUL, Aug. 25 (Korea Bizwire) — South Korea’s major pharmaceutical firm Celltrion Inc. said Friday it has completed a license deal with Johnson & Johnson to sell its autoimmune disease treatment biosimilar in the United States. The deal will allow Celltrion’s CT-P43, the company’s ustekinumab biosimilar referencing Stelara, developed by J&J’s pharmaceutical unit of Janssen [...]